Anagen floats with 15m pounds share placing
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.ANAGEN, which makes sophisticated blood-testing equipment, is coming to the market via a placing that will raise pounds 15m, writes Paul Durman.
Like other bioscience companies, Anagen is still in the development phase, when investment costs exceed revenue. Mervyn Sennett, managing director, said he hoped to begin full commercial marketing of its AN2000 diagnostic system next year.
AN2000 is a computerised box that can handle up to 20 different tests at once. The world market is estimated to be worth dollars 5bn. Anagen also plans a food-testing device.
Anagen has lost pounds 13.3m since its foundation in 1989. It expects to lose another pounds 8m in the next three years before making its first profits in 1996.
Anagen's prospectus warns: 'There can be no assurance that the group will achieve significant revenues or profitable operations.'
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments